Literature DB >> 3794812

Synthesis and characterization of congeners of misonidazole for imaging hypoxia.

Z Grunbaum, S J Freauff, K A Krohn, D S Wilbur, S Magee, J S Rasey.   

Abstract

Misonidazole is a known hypoxic cell sensitizer that binds covalently in hypoxic cells. Its congeners labeled with 77Br, 75Br, or 18F, are likely candidates for imaging hypoxia. We have synthesized and tested [82Br]-4-bromomisonidazole, [3H]-4-bromomisonidazole, [3H]fluoromisonidazole and [3H]misonidazole as prototype radiopharmaceuticals and have compared their uptake in normal and malignant tissues. The higher lipophilicity of brominated misonidazole increased its concentration in the hypoxic portion of tumors at 2 hr, but high blood levels contributed to excessive background, incompatible with imaging. Hydrogen-3-fluoromisonidazole diffused into tumors at a slower rate than misonidazole but it also cleared from normal tissues so that after 2 hr tumor-to-blood ratios favorable for imaging were achieved. In the compounds that were studied, fluorine at the end of the alkyl chain is more stable in vivo than bromine on the imidazole ring. Our results indicate that [18F] fluoromisonidazole may be a useful tracer for imaging hypoxia at approximately 4 hr after injection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3794812

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  14 in total

1.  Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.

Authors:  Keisha C McCall; John L Humm; Rachel Bartlett; Megan Reese; Sean Carlin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-23       Impact factor: 7.038

Review 2.  Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging.

Authors:  James R Fink; Mark Muzi; Melinda Peck; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

3.  Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma.

Authors:  S H Yeh; R S Liu; L C Wu; D J Yang; S H Yen; C W Chang; T W Yu; K L Chou; K Y Chen
Journal:  Eur J Nucl Med       Date:  1996-10

4.  Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole.

Authors:  R S Liu; L S Chu; S H Yen; C P Chang; K L Chou; L C Wu; C W Chang; M T Lui; K Y Chen; S H Yeh
Journal:  Eur J Nucl Med       Date:  1996-10

5.  pH-Responsive Polymers for Improving the Signal-to-Noise Ratio of Hypoxia PET Imaging with [18 F]Fluoromisonidazole.

Authors:  Jeroen A C M Goos; Maria Davydova; Nigel Lengkeek; Ivan Greguric; Michael R Whittaker; John F Quinn; Jonathan B Baell; Jason S Lewis; Thomas P Davis
Journal:  Macromol Rapid Commun       Date:  2020-04-06       Impact factor: 5.734

6.  [(68) Ga]-HP-DO3A-nitroimidazole: a promising agent for PET detection of tumor hypoxia.

Authors:  Yunkou Wu; Guiyang Hao; Saleh Ramezani; Debabrata Saha; Dawen Zhao; Xiankai Sun; A Dean Sherry
Journal:  Contrast Media Mol Imaging       Date:  2015-06-29       Impact factor: 3.161

7.  Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging.

Authors:  Ludwig J Dubois; Natasja G Lieuwes; Marco H M Janssen; Wenny J M Peeters; Albert D Windhorst; Joseph C Walsh; Hartmuth C Kolb; Michel C Ollers; Johan Bussink; Guus A M S van Dongen; Albert van der Kogel; Philippe Lambin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-23       Impact factor: 11.205

8.  18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions.

Authors:  Mark Muzi; Lanell M Peterson; Janet N O'Sullivan; James R Fink; Joseph G Rajendran; Lena J McLaughlin; John P Muzi; David A Mankoff; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2015-06-25       Impact factor: 10.057

9.  Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.

Authors:  Alexander M Spence; Mark Muzi; Kristin R Swanson; Finbarr O'Sullivan; Jason K Rockhill; Joseph G Rajendran; Tom C H Adamsen; Jeanne M Link; Paul E Swanson; Kevin J Yagle; Robert C Rostomily; Daniel L Silbergeld; Kenneth A Krohn
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

Review 10.  Tumor hypoxia: a new PET imaging biomarker in clinical oncology.

Authors:  Nagara Tamaki; Kenji Hirata
Journal:  Int J Clin Oncol       Date:  2015-11-14       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.